Senate Committee on Aging Chairman Sen. Rick Scott (R-Fla.) is raising concerns over Chinese entities participating in U.S. clinical trials and drug approval processes and calling for immediate action from federal health agencies.
In a March 19 letter to federal health authorities, shared with The Epoch Times beforehand, Scott pointed to Bioheng, a China-based clinical-stage company also known as Imviva, as being “reportedly financed by CCP-linked sources,” referring to the acronym for the Chinese Communist Party.
